Dr. Reddy's Laboratories Ltd Common Stock (RDY)

Dr. Reddy's Laboratories (NYSE:RDY) said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphasized that products already supplied to the market are not affected and do not raise patient safety

Dr Reddy's Laboratories (NYSE:RDY) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter. Narasimham said the company’s und

Dr. Reddy's Laboratories exemplifies Peter Lynch's GARP strategy with strong earnings growth, a low PEG ratio, and a debt-free balance sheet.

Dr. Reddy's Labs fits the Peter Lynch investment model with strong EPS growth, a low PEG ratio, minimal debt, and high ROE, making it a compelling GARP stock.

Dr. Reddy's Laboratories aligns with Peter Lynch's GARP strategy, showing strong financial health, steady earnings growth, and an attractive valuation with a low PEG ratio.

Discover Dr. Reddy's (RDY), a Peter Lynch-style GARP stock with strong earnings growth, low debt, and an attractive PEG ratio for long-term value.

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

Dr. Reddy's Laboratories (RDY) exemplifies Peter Lynch's GARP strategy with strong 23.6% EPS growth, a low 0.80 PEG ratio, and excellent financial health.

Discover how Dr. Reddy's Laboratories (RDY) exemplifies Peter Lynch's GARP investing strategy with strong earnings growth, a low PEG ratio, and a robust financial profile.

Dr. Reddy's Labs (RDY) fits Peter Lynch's GARP strategy with steady earnings growth, strong profitability, low debt, and fair valuation—ideal for long-term investors.

DR. REDDY'S LABORATORIES (NYSE:RDY) fits the GARP model with strong earnings growth, solid profitability, and a reasonable valuation, making it a candidate for long-term investors.

DR. REDDY'S LABORATORIES (NYSE:RDY) offers strong historical growth, reasonable valuation, and solid financial health, making it a candidate for GARP investors.

DR. REDDY'S LABORATORIES (NYSE:RDY) fits the GARP mold with strong historical growth, a low PEG ratio, and robust financials, making it a candidate for long-term investors.

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

DR. REDDY'S LABORATORIES (NYSE:RDY) offers strong earnings growth, low debt, and solid profitability, making it a candidate for GARP investors. Read why it fits the Peter Lynch strategy.

Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) fits the characteristics of a Lynch-approved investment.

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Let’s dive into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) using Peter Lynch’s key investing principles, from earnings growth and debt levels to long-term scalability and valuation.